Apheresis in homozygous familial hypercholesterolemia: The results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia

Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia

“…3). These findings are comparable with published studies that have reported LDL-C concentrations of between 5.6 mmol/L and 15.5 mmol/L in treated HoFH patients [2,5,9,10].…”

The Agenda for Familial Hypercholesterolemia

“…All studies were conducted outside the United States and used different methods to assess QOL. [22][23][24][25][26][27] In general, pediatric and adult FH patients receiving dietary and pharmacotherapy have a QOL comparable to that of healthy reference populations. 22,24 Patients appeared to feel safer when taking their medications, but women appear to be more worried about the effects that the medications may have on their or their children's bodies.…”

“…25,26 Relief of angina improves QOL, but frequent testing and other monitoring requirements with apheresis reduce QOL.…”

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

“…Patients who are intolerant of a particular method of LA should be tested on an alternative method, including plasma exchange if required [8,64,153]. Because of the demands of treatment, psychological status and quality of life should be addressed [8], recent data suggesting that lower quality of life may relate specifically to the severity of CVD [161]. Longterm efficacy of treatment on carotid and aortic valve/root atherosclerosis should be assessed every 2 years in homozygotes using standard imaging methods [8,155,162].…”